Merck/Rosetta Scales Up Merck's Genomics Effort, Merger Comfort Level?

Merck's $620 mil. acquisition offer for Rosetta Inpharmatics will scale up Merck's genomics research efforts - and may also scale up its tolerance for mergers and acquisitions.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet